Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

U.S. Food and Drug Administration Approves Gilead's Once-Daily HIV Pill Complera

August 11, 2011

The Food and Drug Administration (FDA) on Wednesday approved the once-daily pill Complera for patients not previously treated for HIV.

Complera, made by Gilead Sciences Inc., combines tenofovir/emtricitabine (Truvada) with rilpivirine (Edurant), a Johnson & Johnson drug that received FDA approval in May. The combination treatment will cost approximately $1,705 a month.

A statement by Gilead said the approval of Complera was supported by data from two 48-week, Phase III studies -- ECHO and THRIVE -- that compared rilpivirine to efavirenz (Sustiva), made by Bristol-Myers Squibb Co., in treatment-naive adults with HIV-1 infection. Most patients in the rilpivirine study arm received Truvada as well.

Gilead stressed consideration of the following before starting patients on Complera:

  • Complera is not recommended for use in patients under age 18.
  • Virologic failure was more common in subjects in the rilpivirine arm who had a baseline HIV-1 RNA of greater than 100,000 copies/mL.
  • Compared to those in the efavirenz arm, virologic failure rate in rilpivirine-treated subjects conferred a higher overall rate of treatment resistance and cross-resistance to the non-nucleoside reverse transcriptase inhibitor class.
  • More subjects treated with rilpivirine developed lamivudine/emtricitabine-associated resistance compared to efavirenz.

Further, Complera has boxed warnings concerning lactic acidosis/severe hepatomegaly with steatosis and post-treatment acute exacerbation of hepatitis B.

For more information, visit www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm267592.htm.

Back to other news for August 2011

Adapted from:
Reuters Health Medical News
08.10.2011


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
FDA Approves Complera (Edurant + Truvada), the Second "All-in-One" Pill for First-Line HIV Treatment
Next Single-Pill HIV Treatment Approved, and It's Not Called "B-Tripla"
Approval of Complera: Emtricitabine/Rilpivirine/Tenofovir DF Fixed-Dose Combination (Official FDA Announcement)
Edurant (Rilpivirine): The HIV Treatment Dating Game Just Got More Interesting
More News & Research on Complera (Rilpivirine/Tenofovir/FTC)

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement